Forte Biosciences (NASDAQ:FBRX – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.11), Zacks reports.
Forte Biosciences Trading Down 21.3 %
NASDAQ FBRX traded down $0.08 during trading on Thursday, hitting $0.31. 1,609,011 shares of the company traded hands, compared to its average volume of 36,442. The company has a market capitalization of $11.19 million, a P/E ratio of -0.35 and a beta of 0.09. The business has a fifty day simple moving average of $0.53 and a 200 day simple moving average of $0.63. Forte Biosciences has a 12 month low of $0.28 and a 12 month high of $0.91.
Wall Street Analyst Weigh In
Separately, Brookline Capital Management began coverage on Forte Biosciences in a research note on Thursday, May 30th. They issued a “buy” rating and a $4.00 price objective for the company.
Forte Biosciences Company Profile
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
Read More
- Five stocks we like better than Forte Biosciences
- Insider Trading – What You Need to Know
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- What is MarketRank™? How to Use it
- Jeff Brown’s Exegesis AI Stock Picks
- Are Penny Stocks a Good Fit for Your Portfolio?
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
